Shared on04 Aug 25Fair value Decreased 21%
Baxter International’s consensus analyst price target has been significantly reduced, primarily driven by downward revisions in both revenue growth forecasts (from 5.2% to 3.7% per annum) and net profit margin (from 7.71% to 7.02%), resulting in a new fair value estimate of $29.89. What's in the News Baxter provided Q3 and full-year 2025 sales guidance, projecting 6–7% reported sales growth from continuing operations and 3–4% operational growth.
Shared on30 Apr 25Fair value Decreased 0.92%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 0.25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.35%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 4.27%
AnalystConsensusTarget has decreased revenue growth from -6.8% to 4.5%, decreased profit margin from 9.3% to 8.4% and increased future PE multiple from 22.1x to 25.9x.